In HNSCC, EGFR and KRAS mutations seem to be rare [12,28]; however, mutation of PIK3CA occurs in 9%–11% of patients [13,14] and has been shown to activate the AKT signaling pathway [14]. This evidence concerns the gene KRAS and head and neck squamous cell carcinoma.